A new drug called Lecanemab is going to the FDA for approval and may be one of the biggest breakthroughs for Alzheimer’s.
The clinical trial has shown to slow memory loss with people suffering from Alzheimer’s over a span of 18 months, according to 13 WHAM.
If the drug is approved, there are almost 410,000 people in the state of New York that can benefit from it.
Studies have shown there is a 27% decrease in cognitive decline after 18 months of use. This drug will help give people more time with their families and the ability to hold onto memories longer.
Negative side effects of the drug include headaches, brain swelling, and brain bleeding, which are serious.
The FDA will start its review of the drug in January. If and when it becomes available to the public is currently unknown.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].